Ascendis Pharma (ASND) Q1 FY26 earnings call

Ascendis Pharma reported a strong Q1 FY26, marked by the FDA approval and successful early launch of YUVIWEL, alongside continued robust uptake of YORVIPATH and SKYTROFA. The company achieved profitability with a 22% non-IFRS operating margin, driven by rapid revenue growth from its diversified endocrine rare disease portfolio. Management reiterated confidence in long-term growth, supported by pipeline expansion and strategic capital allocation, despite some one-time revenue impacts and a decision to discontinue internal oncology development.